1.中山大学附属喀什医院感染科,新疆 喀什844000//中山大学附属第三医院感染科,广东 广州510630//喀什地区第一人民医院感染科,新疆 喀什844000
2.喀什地区第一人民医院感染科,新疆 喀什844000
3.中山大学附属第三医院感染科,广东 广州510630
曾国芬,硕士,主治医师,研究方向:细菌及真菌感染,E-mail:zenggfen@mail.sysu.edu.cn
纸质出版日期:2022-03-20,
收稿日期:2021-10-09,
扫 描 看 全 文
曾国芬,庄江锋,高亮等.布鲁菌病67例临床特征[J].中山大学学报(医学科学版),2022,43(02):297-304.
ZENG Guo-fen,ZHUANG Jiang-feng,GAO Liang,et al.Clinical Characteristics of 67 Cases of Brucellosis[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(02):297-304.
曾国芬,庄江锋,高亮等.布鲁菌病67例临床特征[J].中山大学学报(医学科学版),2022,43(02):297-304. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0216.
ZENG Guo-fen,ZHUANG Jiang-feng,GAO Liang,et al.Clinical Characteristics of 67 Cases of Brucellosis[J].Journal of Sun Yat-sen University(Medical Sciences),2022,43(02):297-304. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2022.0216.
目的
2
分析疫区及非疫区两家三甲医院收治的布鲁菌病(布病)患者的临床特征。
方法
2
回顾性分析2019年1月至2019年12月中山大学附属喀什医院(喀地一院)及中山大学附属第三医院(中山三院)住院的67例布病患者的临床资料,包括人口学资料、病史、症状、体征、实验室检查及治疗方案,比较两地患者临床表现、实验室检查及治疗选择的差异。
结果
2
喀地一院、中山三院分别有23例(43.4%)、11例(78.6%)患者具有明确的流行病学史(
P
=0.019)。发热、乏力、关节疼痛是布病最常见的症状。除了首发纳差症状外,两家医院患者的起病症状大致相同。患者发热、肌肉疼痛发生率及热峰相似,但喀地一院多汗、乏力、关节疼痛、皮疹症状较中山三院常见。两家医院患者均有病例出现肝脾肿大,但均无明显浅表淋巴结肿大。喀地一院、中山三院分别有39例(73.6%)、11例(78.6%)患者发生并发症,院间发生率无统计学差异(
P
=0.971),且均以肝炎和骨骼损害最常见。中山三院患者脊柱炎(
P
=0.042)及神经型布病(
P
=0.041)的发生率高于喀地一院,其余并发症分布无明显统计学差异。喀地一院有7.5%患者使用单药治疗,59.7%使用二联抗菌治疗,均高于中山三院(0、50.0%)。后者使用三联方案的比例高于喀地一院(50.0%
vs.
11.3%)。
结论
2
不同地域布病的临床特征总体类似,但在流行病学史、症状、并发症及治疗方案选择上存在部分差异。临床实践中应结合本地病例的特点综合分析,提高布病的认识,减少误诊、漏诊。
Objective
2
To analyze the clinical characteristics of brucellosis patients from two tertiary hospitals in epidemic and non-epidemic areas.
Methods
2
The clinical data of 67 brucellosis patients hospitalized in The Affiliated Kashi Hospital of Sun Yat-sen University (Kashi, 53) and The Third Affiliated Hospital of Sun Yat-sen University (Guangzhou, 14) from January 2019 to December 2019 were retrospectively reviewed, including demographic data, medical history, symptoms, signs, laboratory tests and treatment, and the differences between the two groups were compared.
Results
2
There were 23 patients in Kashi and 11 patients in Guangzhou with definite epidemiological history, respectively (
P
= 0.019). Fever, fatigue and arthralgia were the most common symptoms of brucellosis. In addition to anorexia, the onset symptoms of patients in the two hospitals were roughly the same. The incidence of fever, muscle pain and fever peak was similar, but the symptoms of hyperhidrosis, fatigue, arthralgia and rash in Kashi were more common in Guangzhou. There were cases of hepatosplenomegaly in both hospitals, but there was no obvious superficial lymphedema. Complications occurred in 39(73.6%) and 11(78.6%) patients in Kashi and Guangzhou, respectively, with no statistical difference (
P
=0.971), and hepatitis and bone damage were the most common. The incidence of spondylitis (
P
=0.042) and neurodegenerative brucellosis (
P
=0.041) in Guangzhou was higher than that in Kashi, and there was no significant difference in other complications. Of the patients in Kashi, 7.5 % were treated with single antibiotics, and 59.7 % were with dual therapy, which were higher than those in Guangzhou (0, 50.0 %). The proportion of the triple scheme in Guangzhou was higher than that of Kashi (50.0 %
vs.
11.3 %).
Conclusions
2
The clinical characteristics of brucellosis in different regions are generally similar, but there are some differences in epidemiological history, symptoms, complications and treatment options. The characteristics of local cases should be concerned in clinical practice to reduce misdiagnosis of brucellosis.
布鲁菌病临床特征
Brucellosisclinical characteristics
Ariza J, Bosilkovski M, Cascio A, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations[J]. PLoS Med, 2007, 4(12): e317.
Lai S, Zhou H, Xiong W, et al. Changing epidemiology of human brucellosis, China, 1955-2014[J]. Emerg Infect Dis, 2017, 23(2): 184-194.
Seleem MN, Boyle SM, Sriranganathan N. Brucellosis: a re-emerging zoonosis[J].Vet Microbiol, 2010, 140(3-4): 392-398.
Yang H, Zhang S, WANG T, et al. Epidemiological characteristics and spatiotemporal trend analysis of human brucellosis in China, 1950-2018[J]. Int J Environ Res Public Health, 2020, 17: 2382.
Ye HY, Xing FF, Yang J, et al. High index of suspicion for brucellosis in a highly cosmopolitan city in southern China[J]. BMC Infect Dis, 2020, 20(1): 22.
李卫, 路恩丽, 张淑敏, 等. 布鲁菌病性脊髓炎1例[J]. 广东医学, 2017, 38(18): 2899.
Li W, Lu EL, Zhang SM, et al. One case of brucellosis myelitis[J]. Guangdong Med J, 2017, 38(18): 2899.
中华人民共和国卫生部. 布鲁氏菌病诊疗指南(试行)[J].传染病信息, 2012, 25(6): 323-324+359.
Ministry of Health of the People's Republic of China. Brucellosis diagnosis and treatment guidelines[J]. Infect Dis Info, 2012, 25(6): 323-324+359.
张文宏, 张跃新.布鲁菌病诊疗专家共识[J].中华传染病杂志, 2017, 35(12): 705-710.
Zhang WH, Zhang YX. Expert consensus on brucellosis diagnosis and treatment[J]. Chin J Infect Dis, 2017, 35(12): 705-710.
Guven T, Ugurlu K, Ergonul O, et al. Neurobrucellosis: clinical and diagnostic features[J]. Clin Infect Dis, 2013, 56(10): 1407-1412.
Zhai J, Peng R, Wang Y, et al. Factors associated with diagnostic delays in human brucellosis in Tongliao city, Inner Mongolia Autonomous Region, China[J]. Front Public Health, 2021, 9: 648054.
Dean AS, Crump L, Greter H, et al. Clinical manifestations of human brucellosis: a systematic review and meta-analysis[J]. PLoS Negl Trop Dis, 2012, 6(12): e1929.
Massasso D, Gibson K. Brucellosis mimicking Henoch-Schonlein purpura[J]. Med J Aust, 2007, 186(11): 602-603.
Akgun C, Akbayram S, Guner S, et al. Brucellosis as a trigger agent for Henoch-Schonlein purpura[J]. Bratisl Lek Listy, 2012, 113(8): 506-507.
Buzgan T, Karahocagil MK, Irmak H, et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature[J]. Int J Infect Dis, 2010, 14(6): 469-478.
Shi Y, Gao H, Pappas G, et al. Clinical features of 2 041 human brucellosis cases in China[J]. PLoS One, 2018, 13(11): e0205500.
Joint FAO/WHO expert committee on brucellosis[J]. World Health Organ Tech Rep Ser, 1986, 740: 1-132.
Solera J. Update on brucellosis: therapeutic challenges[J]. Int J Antimicrob Agents, 2010,36 suppl, S18-20.
Jia B, Zhang F, Lu Y, et al. The clinical features of 590 patients with brucellosis in Xinjiang, China with the emphasis on the treatment of complications[J]. PLoS Negl Trop Dis, 2017, 11(5): e0005577.
Falagas ME, Bliziotis IA. Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies[J]. Antimicrob Agents Chemother, 2006, 50(1): 22-33.
Bboilkovski M, Keramat F, Arapovic J. The current therapeutical strategies in human brucellosis[J]. Infection, 2021, 49(5): 823-832.
Pappas G, Christou L, Akritidis N, et al. Quinolones for brucellosis: treating old diseases with new drugs[J]. Clin Microbiol Infect, 2006, 12(9): 823-825.
He X, Cao M, Mahapatra T, et al. Burden of tuberculosis in Xinjiang between 2011 and 2015: a surveillance data-based study[J]. PLoS One, 2017, 12(11): e0187592.
0
浏览量
0
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构